JP2003532675A - 癌細胞の増殖を阻害しそのアポトーシスを誘導する方法 - Google Patents

癌細胞の増殖を阻害しそのアポトーシスを誘導する方法

Info

Publication number
JP2003532675A
JP2003532675A JP2001581820A JP2001581820A JP2003532675A JP 2003532675 A JP2003532675 A JP 2003532675A JP 2001581820 A JP2001581820 A JP 2001581820A JP 2001581820 A JP2001581820 A JP 2001581820A JP 2003532675 A JP2003532675 A JP 2003532675A
Authority
JP
Japan
Prior art keywords
leukotriene
alkyl
compound
ethyl
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001581820A
Other languages
English (en)
Japanese (ja)
Inventor
アドリアン，トーマス，イー．
Original Assignee
クレイトン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クレイトン ユニバーシティ filed Critical クレイトン ユニバーシティ
Publication of JP2003532675A publication Critical patent/JP2003532675A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001581820A 2000-05-09 2001-05-08 癌細胞の増殖を阻害しそのアポトーシスを誘導する方法 Pending JP2003532675A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21934400P 2000-05-09 2000-05-09
US60/219,344 2000-05-09
PCT/US2001/040697 WO2001085166A1 (en) 2000-05-09 2001-05-08 Methods for inhibiting proliferation and inducing apoptosis in cancer cells

Publications (1)

Publication Number Publication Date
JP2003532675A true JP2003532675A (ja) 2003-11-05

Family

ID=22818912

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001581820A Pending JP2003532675A (ja) 2000-05-09 2001-05-08 癌細胞の増殖を阻害しそのアポトーシスを誘導する方法

Country Status (11)

Country Link
EP (1) EP1326605A4 (zh)
JP (1) JP2003532675A (zh)
KR (1) KR20030019372A (zh)
CN (1) CN1237968C (zh)
AU (1) AU2001261832A1 (zh)
BR (1) BR0110473A (zh)
CA (1) CA2408622A1 (zh)
MX (1) MXPA02010974A (zh)
NO (1) NO20025343L (zh)
NZ (1) NZ522387A (zh)
WO (1) WO2001085166A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5858391B2 (ja) * 2013-04-22 2016-02-10 株式会社栃木臨床病理研究所 抗腫瘍剤

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
EP2034022A1 (en) * 2007-09-10 2009-03-11 Universite Libre De Bruxelles Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus
MX2014008452A (es) 2012-01-10 2014-08-27 Lilly Co Eli Compuesto antagonista del leucotrieno b4.
UA117498C2 (uk) 2013-12-20 2018-08-10 Новартіс Аг Гетероарильні похідні бутанової кислоти як інгібітори lta4h

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30449A (en) * 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
WO1996006604A2 (en) * 1994-08-31 1996-03-07 Eli Lilly And Company Methods for identifying and treating resistant tumors
HUP9904672A2 (hu) * 1997-03-21 2000-05-28 Eli Lilly And Co. Szájüregi laphámrák ellen alkalmazható leukotrién antagonisták
AU1916501A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034135A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
AU1916601A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
CN1390139A (zh) * 1999-11-11 2003-01-08 伊莱利利公司 用于治疗癌症的肿瘤细胞溶解组合物

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5858391B2 (ja) * 2013-04-22 2016-02-10 株式会社栃木臨床病理研究所 抗腫瘍剤
JP2016094403A (ja) * 2013-04-22 2016-05-26 株式会社栃木臨床病理研究所 抗腫瘍剤
US9775836B2 (en) 2013-04-22 2017-10-03 Tochigi Institute Of Clinical Pathology Antitumor agent
US10149846B2 (en) 2013-04-22 2018-12-11 Tochigi Institute Of Clinical Pathology Antitumor agent
US10729683B2 (en) 2013-04-22 2020-08-04 Tochigi Institute Of Clinical Pathology Antitumor agent

Also Published As

Publication number Publication date
EP1326605A4 (en) 2004-03-17
CN1237968C (zh) 2006-01-25
KR20030019372A (ko) 2003-03-06
AU2001261832A1 (en) 2001-11-20
NZ522387A (en) 2003-09-26
EP1326605A1 (en) 2003-07-16
MXPA02010974A (es) 2004-09-06
NO20025343D0 (no) 2002-11-07
NO20025343L (no) 2003-01-09
CN1429111A (zh) 2003-07-09
CA2408622A1 (en) 2001-11-15
BR0110473A (pt) 2003-04-01
WO2001085166A1 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
Xu et al. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression
Mirochnik et al. Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth
Hou et al. VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth
US9463219B2 (en) Method for treating brain cancer using a novel tumor suppressor gene and secreted factor
JP2013510143A (ja) ベンゾヘテロサイクル誘導体の癌の予防及び治療又は癌転移抑制のための用途
CN102300568A (zh) Hif-1蛋白积聚的抑制剂
Nakaki et al. Enhanced transcription of the 78,000-dalton glucose-regulated protein (GRP78) gene and association of GRP78 with immunoglobulin light chains in a nonsecreting B-cell myeloma line (NS-1)
Yokoyama et al. Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination
JP2003532675A (ja) 癌細胞の増殖を阻害しそのアポトーシスを誘導する方法
JP2006507327A (ja) α５β１およびその細胞生存経路を調節する能力
US20040053962A1 (en) Methods for inhibiting proliferation and inducing apoptosis in cancer cells
Xu et al. Ligustilide prevents thymic immune senescence by regulating Thymosin β15-dependent spatial distribution of thymic epithelial cells
JP2004520007A (ja) Ｋｓｈｖ感染の遺伝子発現プロフィール及びｋｓｈｖ感染を処置する方法
Cellai et al. Specific PAF antagonist WEB‐2086 induces terminal differentiation of murine and human leukemia cells
Miyajima et al. Captopril restores transforming growth factor-β type II receptor and sensitivity to transforming growth factor-β in murine renal cell cancer cells
Labialle et al. Characterization of the typical multidrug resistance profile in human uveal melanoma cell lines and in mouse liver metastasis derivatives
JP2006348006A (ja) Ｒａｓ信号伝達経路を標的にする血管新生、細胞増殖及び細胞転移抑制剤
JP2006067968A (ja) ヒト癌細胞の浸潤と転移を阻害する物質およびそのスクリーニング方法
Han et al. The combination of tetracyclines effectively ameliorates liver fibrosis via inhibition of EphB1/2
US20130157959A1 (en) Use of hades as tumor suppressor target
KR102026142B1 (ko) Crif1 억제제를 함유하는 항암 및 암전이 억제용 조성물
WO2023140355A1 (ja) 癌治療薬
KR102571503B1 (ko) 암질환 예방 또는 치료용 조성물
WO2022089602A1 (zh) 诊断和治疗化疗耐药小细胞肺癌的新靶点及其应用
KR102140362B1 (ko) Ei24 단백질 또는 이를 암호화하는 유전자를 유효성분으로 함유하는, 암 예방 및 치료용 약학적 조성물